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Thymomas are rare neoplasms that have an indolent growth with a preferentially intra-
thoracic dissemination pattern. Surgery is currently the standard treatment of thymomas;
however radiotherapy is often used in an adjuvant setting due to a high sensitivity of these
tumors to such treatment. Postoperative entire hemithoracic irradiation has been used in
selected Masaoka stage IVa cases after complete surgical excision of metastatic lesions.
In  the present article, the authors report three cases of Masaoka stage IVa thymoma that
underwent entire hemithorax irradiation after surgical excision of metastatic lesions. The
ﬁrst  two patients presented as stage IVa thymomas. The third case consisted of a pleural
recurrence of a thymoma.Hemithoracic
Radiotherapy
Hemithoracic irradiation with low doses has been used by different authors; the available
data shows that it is a well-tolerated treatment that could potentially lead to better loco-
regional control and increased overall survival.
©  2012 Greater Poland Cancer Centre. Published by Elsevier Urban & Partner Sp. z o.o. All
carcinomas (type C) are designated according to their differen-1.  Background
Thymomas are a rare entity with an incidence of 1.5 new cases
per million per year, representing 20–50% of all anterior medi-
astinal tumors in adults and 15% in children.1–4 They occur
with equal frequency in men  and women and there is no pref-
erence for a particular race or geographic distribution.1–4 It has
a bimodal distribution regarding age at presentation; the ﬁrst
peak occurs in the 4th decade and is associated with myas-
thenia gravis, and the second one occurs in the 7th decade.5–8These are malignant tumors that originate from the
thymic epithelium and usually have an exuberant lym-
phoid component.8–11 The World Health Organization’s (WHO)
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histological classiﬁcation is the most widely used one in
current clinical practice. It is based on cell morphology
and the ratio between lymphocytes and epithelial cells.9–12
Thymomas are classiﬁed according to the shape of the neo-
plastic cells as: type A (spindle or oval), type B (dendritic
or epithelioid) and type C (thymic carcinoma). Type B thy-
momas  are further divided according to the atypia of cells
and proportion of thymocytes relative to lymphocytes: B1
thymomas are the richest in lymphocytes and B3 have a
marked cellular atypia and rare lymphocytes.9–12 Thymictiation as: squamous cell, neuroendocrine, mucoepidermoid,
basaloid, lymphoepithelioma, sarcomatoid, clear cell and
papillary.9,10
ed by Elsevier Urban & Partner Sp. z o.o. All rights reserved.
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Fig. 1 – Entire left hemithorax and mediastinum volume.reports of practical oncology and 
Thymomas have an indolent growth, 33% of patients
re asymptomatic at presentation. Of the remaining (symp-
omatic) cases, 30–65% are associated with myasthenia
ravis.1,8,10
The most widely adopted staging system is the one pro-
osed by Masaoka. Lesions are staged according to the degree
f spread as follows: stage I, completely encapsulated lesions;
tage II, lesions with micro or macroscopic capsular invasion;
tage III, lesions that invade adjacent organs (great vessels,
ung, pericardium) and stage IV, disseminated disease, which
s subdivided into IVa (pleural or pericardial implants) and IVb
embolic metastases).1,8,10–12
Surgery is currently the treatment of choice for thymomas.
he criteria that need to be taken into account when decid-
ng if and which adjuvant therapies are needed are: stage,
istological grade and surgical margins. Adjuvant irradiation
f tumor bed seems to be beneﬁcial in stage I patients with
ncomplete resections, and all stages II and III patients, due
o high recurrence rates even after complete resection.13–20
he method by which radiation is delivered is also important
favoring high energy photons), as it has been demonstrated
hat it is an independent prognostic factor for overall survival
OS).21
In the meta-analysis by Korst and colleagues14 the addition
f adjuvant radiotherapy to surgical treatment reduced the
ercentage of recurrence in stage II, from 0–62% to 0–25% and
n stage III, from 13–80% to 0–64%.
As documented in the literature, the most common sites of
isease recurrence are: the pleural membranes, the lung, the
ericardium and the diaphragm.19,20,22–25
Stage IVa thymomas and regional (intra-thoracic) recur-
ence are challenging in terms of treatment approach.
lthough considered a disseminated disease, pleural and peri-
ardial lesions are often resectable and high survival rates are
chievable.20,22–24 Several authors have managed cases with
xtensive pleural disease treated with pleurectomy followed
y total hemithoracic low dose irradiation, with good results
nd low morbidity.20,22–26
Three clinical cases are presented in the following section:
wo patients with stage IVa thymoma at diagnosis and one
ith pleural recurrence. All patients underwent surgical exci-
ion of pleural implants and total hemithoracic irradiation.
.  Case  1
orty-one-year-old female, diagnosed with myasthenia gravis
fter the study of a persistent fatigue and asthenia. The com-
uterized tomography (CT) acquired in April 2009 revealed a
 cm ×3.5 cm anterior mediastinal lesion suggestive of thy-
oma  as well as areas of thickening of the left pleura.
In June 2009, the patient underwent thoracoscopical
esection of the thymoma. The histological results revealed a
redominantly lymphocytic thymoma with an epithelial com-
onent, type B1. Biopsies were also taken of the suspicious
leural lesions that were diagnosed as metastasis of thymoma
ype B1. This yielded a Masaoka stage IVa.
An octreotide scan and a 18FDG-PET/CT were also per-
ormed; the ﬁrst did not show any anomalous uptake of
he radionuclide, while the other revealed multiple foci ofincreased metabolism along the left posterior pleura and
two foci in the base of the ipsilateral lung. The multidisci-
plinary tumor board proposed 5 cycles of chemotherapy with
cyclophosphamide, adriamycin and cisplatin (CAP) which
ended in October 2009. After chemotherapy a second evalu-
ation with 18FDG-PET/CT revealed a persistent disease.
It was decided to submit the patient to parietal and vis-
ceral pleurectomy and excision of the peripheral pulmonary
lesions. The pathological ﬁndings were consistent with pul-
monary and pleural metastasis of type B1 thymoma, R0
resection.
Subsequently, the patient underwent entire hemithorax
and anterior mediastinum radiotherapy.
The entire left hemithorax received 12 Gy in 12 fractions
of 1 Gy, 5 times a week with a three ﬁeld technique (antero-
posterior, postero-anterior and cranial–caudal right posterior
oblique) with 6 MV photons plus 45 Gy in 25 fractions of 1.8 Gy,
5 days a week to the anterior mediastinum through 2 ﬁelds
(anterior oblique and posterior oblique) with 6 MV  photons
(Figs. 1 and 2).
There were no complications during treatment. At the end
of the treatment, the patient presented asthenia and dyspnea
with ordinary effort. Respiratory sounds were equal bilaterally.
This patient changed residency and was lost to follow-up.
3.  Case  2
Thirty-four-year-old female, presented with a history of non-
productive cough, moderate dyspnea and weight loss.
A thorax CT was performed which showed extensive right
pleural effusion, mediastinal shift to the left side, multiple
right pleural suspicious lesions, the largest of them sized
13 cm ×8 cm.  The ﬁne needle biopsy was compatible with thy-
moma.
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Fig. 2 – Anterior mediastinum volume. Fig. 3 – Right hemithorax and mediastinum volume.
as thymoma metastases, R1 resection.Assessment with an octreotide scan revealed an increased
uptake of the radionuclide in the right hemithorax with exten-
sive involvement of the anterior and posterior mediastinum.
18FDG-PET/CT showed increased metabolism involving the
entire right pleura.
The tumor board decided to treat the patient with 6 cycles
of chemotherapy: cyclophosphamide, adriamycin, cisplatin
(CAP) plus prednisolone.
The post chemotherapy 18FDG-PET/CT showed partial
response with persistent uptake foci in the thymus and pleura.
In February 2010, the patient was submitted to thymec-
tomy and total parietal pleurectomy including resection of the
pericardial and diaphragmatic pleura. Histologic examination
revealed a type B2/B3 cortical thymoma with pleural invasion,
R0 ressection.
Then, she underwent adjuvant radiotherapy to the entire
hemithorax and anterior mediastinum.
The entire right hemithorax (Fig. 3) received 12 Gy in 12
fractions of 1 Gy, 5 times a week with a two ﬁeld technique
(antero-posterior and postero-anterior) with 6 MV photons,
plus 45 Gy in 25 fractions of 1.8 Gy, 5 days a week to the ante-
rior mediastinum (Fig. 4) through 4 ﬁelds (antero-posterior,
postero-anterior, right oblique and left anterior oblique) with
6 MV  photons (Figs. 3 and 4).
There were no complications during treatment. At the end
of the treatment, the patient presented a right chest pain, but
no respiratory symptoms. Pulmonary auscultation revealed
diminished respiratory sounds on the base of the right lung.
Three months after RT, the patient reported asthenia, dys-
pnea on doing more  than ordinary effort, and right thoracic
pain. Pulmonary sounds on the base of the right lung were
diminished.
On December 2011, the patient had no symptoms or any
evidence of recurrent disease.4.  Case  3
Fifty-two-year-old male, diagnosed with Masaoka stage III thy-
moma  B3 in 2000 after total thymectomy. Between July and
August 2000, he was submitted to adjuvant radiotherapy to
the anterior mediastinum (total dose of 45 Gy in 25 fractions
with 6 MV  photons).
In 2005, the patient underwent surgical excision of right
pleural suspicious lesions that were pathologically diagnosedFig. 4 – Anterior mediastinum volume.
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The patient completed six cycles of chemotherapy with cis-
latin, vincristine, doxorubicin and cyclophosphamide (ADOC
egimen) by December 2005.
In 2007, a pleural recurrence was diagnosed and he was
ubmitted to 11 cycles of chemotherapy – FOLFOX – achieving
 complete remission (assessed by 18FDG-PET/CT).
Due to a new pleural relapse in 2008, the patient was once
gain subjected to chemotherapy – Carboplatin and Pacli-
axel – achieving stabilization of the disease until March 2010.
ecause of disease progression, the patient underwent an
ncomplete surgical excision of pleural lesions that were also
ompatible with pleural metastases of thymoma.
The tumor board then proposed entire hemithorax irradi-
tion, which the patient accepted.
The patient performed 3D conformal radiotherapy with the
ollowing plan: 12 Gy to the entire right hemithorax (Fig. 5)
n 12 fractions of 1 Gy each, 5 days a week, using 6 MV  pho-
ons through 4 ﬁelds (antero-posterior, postero-anterior, right
ateral and left lateral).
There were no complications during treatment. At the end
f the treatment the patient reported no respiratory or any
ther signiﬁcant symptoms. Pulmonary sounds were dimin-
shed on the inferior half of the right lung.
On December 2011, the patient had no symptoms or any
vidence of recurrent disease.
.  Discussion
iven the rarity of thymomas, its therapeutic approach has
een evaluated solely in retrospective series. Furthermore, the
herapeutic management of stage IVa is only mentioned in
mall series and case-reports.In the initial Masaoka publications, patients with initial
tage IV (including IVa and IVb) had survival rates of approxi-
ately 50% at 5 years and 0% at 10 years.24 Since then, several
uthors have argued that a multimodal treatment approachtherapy 1 7 ( 2 0 1 2 ) 384–388 387
may increase the resectability of the disease and reduce recur-
rence rates.20
This multimodal approach should include preoperative or
postoperative chemotherapy,1,2,4,20,25 extensive surgery with
maximum possible resection of the pleural disease and post-
operative radiotherapy to the thymic bed with low dose
irradiation to the entire involved hemithorax.24–26
In these stages, the most widely used chemotherapy
schemes in the literature are based on cisplatin or doxo-
rubicin, including ADOC (cisplatin, doxorubicin, vincristine
and cyclophosphamide) and PAC (cisplatin, cyclophos-
phamide, and doxorubicin) with or without the addition of
corticosteroids.1,2,20,25 The review performed by Kondo20 that
included thymomas in advanced stages (III and IV) conﬁrmed
the beneﬁt of adding chemotherapy, since it allowed to achieve
an objective response in 67–100% of patients and complete
responses in about 33%.
The surgical treatment of stage IVa (or pleural recurrence)
cases consists in the maximum possible resection of all pleu-
ral and/or pericardial implants using, if necessary, extensive
pleurectomy or resection of the pericardium. Despite the
aggressiveness of this approach, Huang et al.25 presented a
series of 18 patients who underwent pleurectomy and wedge
resections of involved lung with low morbidity, no operative
mortality and high OS.
The rationale of using post-operative hemithoracic irradi-
ation is based on three main points: the known sensitivity
of such tumors to radiation; the known application of this
radiotherapy technique in mesotheliomas after extra-pleural
pneumonectomy and the fact that the risk of recurrence of
the disease is much higher loco-regionally than distantly.8,10,14
In this context, radiotherapy doses more  often reported have
been between 11.2 Gy and 16 Gy in 7–10 fractions.
Uematsu et al.27 used total hemithoracic irradiation pro-
phylactically in stages II and III, using doses between 10–16 Gy
in 10–16 fractions. Recurrence-free survival of 100% at 5
years was achieved in the entire hemithorax irradiation group
(with good clinical tolerance) versus 66% in the group that
only received radiotherapy to the thymic bed. This reinforces
the idea that the addition of radiotherapy is beneﬁcial and
produces low side effects.
According to Huang et al.,25 this multimodal approach
achieves OS rates of 91%, 78% and 65% at 3, 5 and 10
years, respectively, which is much higher than initially
reported.24
6.  Conclusion
There are few studies about the optimal therapeutic approach
for stage IVa thymomas. Some publications report that for
selected patients in stage IVa, postoperative (excision of
metastatic lesions) radiotherapy to the entire hemithorax with
doses ranging from 11 to 16 Gy with fractions of 1–1.6 Gy
should be considered.Total hemithoracic irradiation after resection of pleural
lesions, appears to reduce the risk of pleural recurrence with
acceptable toxicity. This could potentially lead to improve-
ment in OS rates.
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Prospective multicenter studies are needed to assess and
validate the effectiveness of this modality approach to treat
Masaoka stage IVa thymoma.
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